Market Overview:
Point-of-care diagnostics (POC) refers to medical testing performed directly at or near the site of patient care, bypassing the need for centralized laboratories or hospital settings. These tests are designed to deliver quick and accurate results, empowering healthcare providers to make timely and informed decisions regarding patient diagnosis and treatment. The primary benefit of POC diagnostics is its ability to facilitate immediate decision-making, eliminating the wait for test results and reducing the need for patients to travel to distant healthcare facilities.
The field of point-of-care diagnostics is rapidly evolving, bringing substantial advancements that are improving the efficiency and accessibility of healthcare services. This transformation is particularly significant in the Asia-Pacific region, where healthcare systems are under pressure to meet the needs of large and diverse populations. The growing adoption of POC solutions is helping healthcare providers streamline diagnostic processes and make healthcare more efficient and patient-friendly.
Several factors are driving the growth of the point-of-care diagnostics market across Asia-Pacific. The rise in chronic diseases such as diabetes, cardiovascular diseases, respiratory diseases, and cancer across the Asia-Pacific region is one of the primary drivers for the POC diagnostics market. The growing aging population, especially in countries like China, Japan, and India, has resulted in a higher incidence of these conditions. POC testing devices such as blood glucose meters, cholesterol testing kits, and cardiac marker testing devices are gaining popularity for the management and early detection of chronic diseases.
Countries like China and India are seeing a rapid rise in non-communicable diseases, particularly diabetes and cardiovascular diseases, which has led to the greater adoption of POC solutions for continuous monitoring and early detection. Furthermore, the aging populations in countries such as Japan are contributing to the demand for more accessible and efficient diagnostic solutions. The growing trend of home-based testing is also gaining momentum in the region, making it easier for patients to manage their health from home, especially in rural and remote areas where access to healthcare facilities may be limited.
Market Size and Forecast:
According to the DataM market research report, the Asia-Pacific point-of-care diagnostics market size is valued at USD 3.57 billion in 2024, it is expected to reach USD 8.65 billion by 2033, with growth at a CAGR of 10.4% over the forecast period 2024-2033.
Asia-Pacific Point-of-Care Diagnostics Market Segmentation
By Product
- Infectious Disease Testing Products
- Blood Glucose Products
- Blood Gas & Electrolyte Products
- Hematology Testing Products
- Urinalysis Products
- Pregnancy and Fertility Testing Products
- Tumor/Cancer Profiling Products
- Drug-of-Abuse Products
- Others
By Technology
- Lateral Flow Assays
- Immunoassays
- Molecular Diagnostics
- Microfluidics
- Others
By Application
- Infectious Diseases
- Hematology
- Cardiology
- Endocrinology
- Oncology
- Drug Testing
- Neurology
- Others
By End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Home Care Settings
- Ambulatory Surgery Centers (ASCs)
By Country
- China
- Japan
- India
- South Korea
- Rest of Asia-Pacific
Recent Developments in the Industry:
- In January 2023, Cipla Limited, based in India, announced the launch of Cippoint, a point-of-care (POC) testing device designed to provide rapid and reliable diagnostic results for a broad range of health conditions. This device is aimed at transforming healthcare by enabling quick diagnostic tests to be conducted in settings where immediate results are crucial, such as clinics, emergency rooms, hospitals, and even home care settings.
- In April 2024, Roche Diagnostics India launched a heart failure test designed specifically for individuals with diabetes, in the form of a point-of-care (POC) device. This new development marks an important step in addressing the growing need for faster, more accurate diagnostics, particularly for diabetic patients who are at higher risk for heart failure.
Major Companies:
Major companies involved in the Asia-Pacific point-of-care diagnostics market include Abbott, F. Hoffmann-La Roche Ltd., Danaher Corporation, Siemens Healthineers AG, SEKISUI MEDICAL CO., LTD., BD, BioMérieux, QIAGEN, QuidelOrtho Corporation, and Trinity Biotech Plc, among others.
The Full Report has the following insights:
- The report offers a comprehensive evaluation of the market in terms of market value (US) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2018-2033), and verifiable projections about market size during the forecast period (2024-2033).
- Visualize the composition of the Asia-Pacific point-of-care diagnostics market segmentation by product, technology, application, end-user, and region, highlighting the key commercial assets and players.
- Identify commercial opportunities in the Asia-Pacific point-of-care diagnostics market by analyzing trends and co-development deals.
- The report also covers data insights on various industry forces such as Porter's five forces analysis, supply chain analysis, pricing analysis, and regulatory analysis.
- Excel data sheet with thousands of data points of the Asia-Pacific point-of-care diagnostics market -level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in Excel for the key product of all major market players
- The report will provide access to approximately 61 market data tables, 64 figures, and close to 180 pages.